Issue 39, 2018

Diflunisal-adjoined cobalt(iii)-polypyridyl complexes as anti-cancer stem cell agents

Abstract

We report a novel series of cobalt(III)-polypridyl complexes, 4–6, that can selectively release diflunisal, a nonsteroidal anti-inflammatory drug, under reducing conditions. Remarkably, the 1,10-phenanthroline-bearing complex 5 displays selective potency towards hard-to-kill cancer stem cells (CSCs) (IC50 = 2.1 ± 0.1 μM) over bulk cancer (IC50 = 3.9 ± 0.2 μM) and normal cells (IC50 = 21.2 ± 1.3 μM). This complex induces CSC apoptosis by DNA damage and cyclooxygenase-2 inhibition.

Graphical abstract: Diflunisal-adjoined cobalt(iii)-polypyridyl complexes as anti-cancer stem cell agents

Supplementary files

Article information

Article type
Communication
Submitted
24 Aug 2018
Accepted
10 Sep 2018
First published
10 Sep 2018

Dalton Trans., 2018,47, 13761-13765

Diflunisal-adjoined cobalt(III)-polypyridyl complexes as anti-cancer stem cell agents

D. O. Abe, A. Eskandari and K. Suntharalingam, Dalton Trans., 2018, 47, 13761 DOI: 10.1039/C8DT03448F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements